Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Inhibition of CDK Activity

Inhibition of CDK Activity

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Loss of Tumor Suppressor Gene Functions

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

Loss of Tumor Suppressor Gene Functions

Loss of Tumor Suppressor Gene Functions

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Enzyme-Regulated Non-Thermal Fluctuations Enhance Ligand Diffusion and Receptor-Mediated Endocytosis.

Small (Weinheim an der Bergstrasse, Germany)·2026

Same author

An S752D activation loop mutation dynamically primes Muscle-Specific Kinase for activation.

The Biochemical journal·2026

Same author

Subtle Presentation of Type B Esophageal Atresia.

Cureus·2026

Same author

MYC and AP-1 oncogenes cooperatively bind enhancers to rewire transcription.

NAR cancer·2026

Same author

Modeling tumor transport and growth with poroelastic biopolymer networks.

Soft matter·2026

Search research articles

Related Experiment Video

Updated: Mar 22, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Deletion Mutations Keep Kinase Inhibitors in the Loop.

Daniel M Freed¹, Jin H Park¹, Ravi Radhakrishnan²

¹Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.

|April 13, 2016

Summary

Tailoring cancer drugs to tumor mutations is key. Activating deletions in BRAF, EGFR, and HER2 can cause resistance to common kinase inhibitors, guiding better drug selection.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Mar 22, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Effective use of kinase inhibitors depends on matching drugs to specific tumor mutations.
Understanding resistance mechanisms is crucial for optimizing cancer therapy.

Purpose of the Study:

To investigate how activating deletions in key genes like BRAF, EGFR, and HER2 contribute to primary resistance against common kinase inhibitors.
To propose strategies for improved selection of kinase inhibitors based on tumor genetic profiles.

Main Methods:

Analysis of tumor genetic alterations, specifically activating deletions in BRAF, EGFR, and HER2.
Evaluation of the impact of these deletions on the efficacy of clinically relevant kinase inhibitors.

Main Results:

Identified specific activating deletions in BRAF, EGFR, and HER2 as a cause of primary resistance to certain kinase inhibitors.
Demonstrated that these genetic alterations necessitate alternative or combination therapeutic strategies.

Conclusions:

Tumor-specific genetic profiling is essential for effective kinase inhibitor therapy.
Identifying resistance-mediating deletions can guide the selection of more effective targeted treatments for cancer patients.